Ethanol induces upregulation of the nerve growth factor receptor CD271 in human melanoma cells via nuclear factor-κB activation

Rappa,Germana; Anzanello,Fabio; Lorico,Aurelio

doi:10.3892/ol.2015.3343

Ethanol induces upregulation of the nerve growth factor receptor CD271 in human melanoma cells via nuclear factor-κB activation

Authors:
- Germana Rappa
- Fabio Anzanello
- Aurelio Lorico
View Affiliations

Affiliations: Cancer Research Center, Roseman University College of Medicine, Las Vegas, NV 89135, USA
Published online on: June 9, 2015 https://doi.org/10.3892/ol.2015.3343
Pages: 815-821
Copyright: © Rappa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alcohol consumption is one of the most important, and potentially avoidable, risk factors of human cancer, accounting for 3.6% of all types of cancer worldwide. In a recent meta‑analysis, a 20% increased risk of melanoma was linked with regular alcohol consumption. In the present study, the effect of ethanol exposure on the expression of the nerve growth factor receptor, CD271, in human FEMX‑I melanoma cells was investigated. Consistent with the derivation of melanocytes from the neural crest, the majority of melanomas express CD271, a protein that is crucial for maintaining the melanoma stem cell properties, including the capacity of self‑renewal and resistance to chemotherapy and radiotherapy. Analysis of CD271‑sorted subpopulations and clones of FEMX‑I cells indicated no hierarchical organization of CD271+ and CD271‑ cells. In addition, CD271 expression was lost upon growth of FEMX‑I melanoma cells in cancer stem cell‑like conditions, while it was greatly increased upon CD133 knockdown or exposure to ethanol. After 24‑h exposure to 100, 200 and 400 mM ethanol, the percentage of CD271+ cells increased from 14% in control cells to 24, 35 and 88%, respectively. An increase in the percentage of CD271+ cells was already evident 8 h after ethanol exposure and reached a maximum at 48 h. Ethanol‑induced upregulation of CD271 was mediated by nuclear factor‑κB (NF‑κB). In fact, exposure of FEMX‑I cells to 100‑400 mM ethanol for 24 h resulted in a concentration‑ and time‑dependent increase in NF‑κB activity, up to 900% that of control cells. NF‑κB activation was due to a decrease in p50 homodimers, which occupy the NF‑κB binding site, blocking transactivation. No effects of ethanol on 9 additional signaling pathways of FEMX‑I cells were observed. In the presence of CD271 blocking antibodies, NF‑κB activation was not prevented, indicating that ethanol did not target CD271 directly. These data demonstrate that ethanol induces expression of CD271 in FEMX‑I cells via NF‑κB activation and indicate a possible molecular link between ethanol exposure and melanoma formation.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Pelucchi C, Tramacere I, Boffetta P, Negri E and La Vecchia C: Alcohol consumption and cancer risk. Nutr Cancer. 63:983–990. 2011. View Article : Google Scholar : PubMed/NCBI
3	Boffetta P and Hashibe M: Alcohol and cancer. Lancet Oncol. 7:149–156. 2006. View Article : Google Scholar : PubMed/NCBI
4	Mancebo SE and Wang SQ: Skin cancer: role of ultraviolet radiation in carcinogenesis. Rev Environ Health. 29:265–273. 2014. View Article : Google Scholar : PubMed/NCBI
5	Gandini S, Sera F, Cattaruzza MS, et al: Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 41:45–60. 2005. View Article : Google Scholar : PubMed/NCBI
6	Rota M, Pasquali E, Bellocco R, et al: Alcohol drinking and cutaneous melanoma risk: a systematic review and dose-risk meta-analysis. Br J Dermatol. 170:1021–1028. 2014. View Article : Google Scholar : PubMed/NCBI
7	Chesa PG, Rettig WJ, Thomson TM, Old LJ and Melamed MR: Immunohistochemical analysis of nerve growth factor receptor expression in normal and malignant human tissues. J Histochem Cytochem. 36:383–389. 1988. View Article : Google Scholar : PubMed/NCBI
8	Pietra G, Manzini C, Vitale M, et al: Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol. 21:793–801. 2009. View Article : Google Scholar : PubMed/NCBI
9	Boiko AD, Razorenova OV, van de Rijn M, et al: Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 466:133–137. 2011. View Article : Google Scholar
10	Civenni G, Walter A, Kobert N, et al: Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 71:3098–3109. 2011. View Article : Google Scholar : PubMed/NCBI
11	Barker PA and Shooter EM: Disruption of NGF binding to the low affinity neurotrophin receptor p75LNTR reduces NGF binding to TrkA on PC12 cells. Neuron. 13:203–215. 1994. View Article : Google Scholar : PubMed/NCBI
12	Dobrowsky RT, Werner MH, Castellino AM, Chao MV and Hannun YA: Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor. Science. 265:1596–1599. 1994. View Article : Google Scholar : PubMed/NCBI
13	Shonukan O, Bagayogo I, McCrea P, Chao M and Hempstead B: Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin. Oncogene. 22:3616–3623. 2003. View Article : Google Scholar : PubMed/NCBI
14	Rappa G, Fodstad O and Lorico A: The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells. 26:3008–3017. 2008. View Article : Google Scholar : PubMed/NCBI
15	Fodstad O, Kjønniksen I, Aamdal S, Nesland JM, Boyd MR and Pihl A: Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res. 48:4382–4388. 1988.PubMed/NCBI
16	Schneider CA, Rasband WS and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
17	Secchiero P, Milani D, Gonelli A, et al: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-κB-dependent maturation of normal and leukemic myeloid cells. J Leukoc Biol. 74:223–232. 2003. View Article : Google Scholar : PubMed/NCBI
18	Bauer NN, Chen YW, Samant RS, Shevde LA and Fodstad O: Rac1 activity regulates proliferation of aggressive metastatic melanoma. Exp Cell Res. 313:3832–3839. 2007. View Article : Google Scholar : PubMed/NCBI
19	Anderson DM, Maraskovsky E, Billingsley WL, et al: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:175–179. 1997. View Article : Google Scholar : PubMed/NCBI
20	Sonenshein GE: Rel/NF-κB transcription factors and the control of apoptosis. Semin Cancer Biol. 8:113–119. 1997. View Article : Google Scholar : PubMed/NCBI
21	Siebenlist U, Franzoso G and Brown K: Structure, regulation and function of NF-κB. Annu Rev Cell Biol. 10:405–455. 1994. View Article : Google Scholar : PubMed/NCBI
22	Gukovskaya AS, Mouria M, Gukovsky I, et al: Ethanol metabolism and transcription factor activation in pancreatic acinar cells in rats. Gastroenterology. 122:106–118. 2002. View Article : Google Scholar : PubMed/NCBI
23	Huang S, DeGuzman A, Bucana CD and Fidler IJ: Nuclear factor-κB activity correlates with growth, angiogenesis and metastasis of human melanoma cells in nude mice. Clin Cancer Res. 6:2573–2581. 2000.PubMed/NCBI
24	Yang J and Richmond A: Constitutive IκB kinase activity correlates with nuclear factor-κB activation in human melanoma cells. Cancer Res. 61:4901–4909. 2001.PubMed/NCBI
25	Kurbanov BM, Fecker LF, Geilen CC, Sterry W and Eberle J: Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4. Oncogene. 26:3364–3377. 2007. View Article : Google Scholar : PubMed/NCBI
26	Toesca A, Giannetti S and Granato A: Overexpression of the p75 neurotrophin receptor in the sensori-motor cortex of rats exposed to ethanol during early postnatal life. Neurosci Lett. 342:89–92. 2003. View Article : Google Scholar : PubMed/NCBI
27	Cosgaya JM and Shooter EM: Binding of nerve growth factor to its p75 receptor in stressed cells induces selective IκB-beta degradation and NF-κB nuclear translocation. J Neurochem. 79:391–399. 2001. View Article : Google Scholar : PubMed/NCBI
28	Bhakar AL, Roux PP, Lachance C, Kryl D, Zeindler C and Barker PA: The p75 neurotrophin receptor (p75NTR) alters tumor necrosis factor-mediated NF-κB activity under physiological conditions, but direct p75NTR-mediated NF-κB activation requires cell stress. J Biol Chem. 274:21443–21449. 1999. View Article : Google Scholar : PubMed/NCBI
29	Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Wruck W, Yaspo ML, Lehrach H, Schäfer R and Regenbrecht CR: The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PLoS One. 9:e925962014. View Article : Google Scholar : PubMed/NCBI
30	Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G and La Porta CA: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 43:935–946. 2007. View Article : Google Scholar : PubMed/NCBI
31	Chan MM and Tahan SR: Low-affinity nerve growth factor receptor (P75 NGFR) as a marker of perineural invasion in malignant melanomas. J Cutan Pathol. 37:336–343. 2010. View Article : Google Scholar : PubMed/NCBI
32	Morrison LC, McClelland R, Aiken C, Bridges M, Liang L, Wang X, Di Curzio D, Del Bigio MR and Taylor MD: Werbowetski-Ogilvie TE: Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes. Neoplasia. 15:384–398. 2013. View Article : Google Scholar : PubMed/NCBI